Eye-tracking data

ViewMind’s patented Digital Biomarker software, based on AI, can identify minor alterations in oculomotor patterns and correlate them to specific pathologies, cognitive functions and related areas of the brain

After completing a 15 minutes evaluation, the information is uploaded and processed in ViewMind’s cloud server, and the results are generated automatically within seconds.

Centralized

servers

Artificial

Intelligent

algorithms

Automatized

results

NEUROCOGNITIVE DIGITAL BIOMARKERS POWERED BY A.I.

ViewMind is a revolutionary digital health and AI company with clinically validated solutions for the early diagnosing of dementia

THE TECHNOLOGY

After conclusive clinical validation, ViewMind has established a unique degree of accuracy, with a 15 minutes test approach that can forever change the management of dementia.

Early Onset Screening

Validated on a longitudinal study, ViewMind is able to discriminate patients with Mild Cognitive Impairment who will develop Alzheimer’s or other neuro-degenerative diseases, years before Clinical Diagnostic

Digital Biomarker

ViewMind has higher Sensitivity and Specificity than Complete Neurocognitive Batteries and Complex Neuroimages. Clinical Protocols show levels of accuracy comparable with Spinal Fluid Extraction and a B- Amyloid PET in the early stages of Alzheimer’s, up to 20 years before symptoms.

Gerardo Fernandez PhD

Matias Shulz

Nuerocientific

Officer

CSO

CEO

Mario Parra M.D. PhD

David Orozco M.D.

Ariel Arelovich PhD

CMO

CTO

Executive

Chairman

Mark Edwards

Together with a third-party medical grade VR headset and specific stimuli, ViewMind 15-minutes evaluations can give actionable information for physicians to properly diagnose and define a course of action.